Davies M J, Rumbold A R, Moore V M
1Lifecourse and Intergenerational Health,The Robinson Institute,University of Adelaide,Adelaide,Australia.
J Dev Orig Health Dis. 2017 Aug;8(4):443-447. doi: 10.1017/S2040174417000526.
The use of assisted reproductive technologies (ART) for the treatment of infertility has grown exponentially over the last 20 years, and now accounts for 4% of all births in Australia, and over 1 m births annually around the globe. There is consistent reporting of increased risk of adverse perinatal outcomes and birth defects following infertility treatment. However, change in practice has been stymied by critical knowledge gaps with regards to (a) the relative contribution of patient and treatment factors to adverse outcomes, (b) the independent contribution of specific contemporary treatments and treatment combinations to outcomes, (c) the impact of innovations in laboratory and clinical practice on treatment success and observed risk and (d) changes over time in patient characteristics. Here we summarize key findings from the South Australian Birth Cohort, which is a whole-of-population cohort of over 300,000 births from 1986 to 2002. Relative to spontaneous conceptions, singletons from assisted conception were more likely to be stillborn [odds ratio (OR)=1.82; 95% confidence interval (CI) 1.34-2.48], while survivors as a group were comprehensively disadvantaged at birth, including lower birth weight (OR=2109 g; 95% CI 2129-289), very low birth weight (OR=2.74; 95% CI 2.19-3.43), very preterm birth (OR=2.30; 95% CI 1.82-2.90) and neonatal death (OR=2.04; 95% CI 1.27-3.26). Major birth defects, including cardiac, urogenital and musculoskeletal defects are doubled after fresh ICSI cycles, which is a particular concern as ICSI now accounts for 70% of all treatment cycles globally. Future study is needed to provide contemporary, precise evidence to inform patient and clinic decision making, and generate knowledge for future innovation in ART laboratory methods and clinical practice, thereby optimizing treatment and health outcomes while reducing adverse events.
在过去20年中,辅助生殖技术(ART)用于治疗不孕症的情况呈指数级增长,目前在澳大利亚所有出生婴儿中占4%,在全球每年超过100万例出生中占一定比例。一直有报道称,不孕症治疗后围产期不良结局和出生缺陷的风险增加。然而,实践中的改变因以下关键知识空白而受阻:(a)患者因素和治疗因素对不良结局的相对贡献;(b)特定当代治疗方法和治疗组合对结局的独立贡献;(c)实验室和临床实践中的创新对治疗成功率和观察到的风险的影响;(d)患者特征随时间的变化。在此,我们总结了南澳大利亚出生队列的主要研究结果,该队列是1986年至2002年超过30万例出生的全人群队列。与自然受孕相比,辅助受孕的单胎死产可能性更大[比值比(OR)=1.82;95%置信区间(CI)1.34 - 2.48],而存活者作为一个群体在出生时普遍处于劣势,包括出生体重较低(OR = 2109克;95% CI 2129 - 289)、极低出生体重(OR = 2.74;95% CI 2.19 - 3.43)、极早产(OR = 2.30;95% CI 1.82 - 2.90)和新生儿死亡(OR = 2.04;95% CI 1.27 - 3.26)。包括心脏、泌尿生殖和肌肉骨骼缺陷在内的主要出生缺陷在新鲜卵胞浆内单精子注射(ICSI)周期后增加了一倍,这是一个特别令人担忧的问题,因为ICSI目前占全球所有治疗周期的70%。需要进一步研究以提供当代精确证据,为患者和诊所决策提供依据,并为ART实验室方法和临床实践的未来创新生成知识,从而在减少不良事件的同时优化治疗和健康结局。